Thermo Fisher Scientific

Labroots Announces Agenda for its 7th Annual Drug Discovery & Development Virtual Event on February 21, 2024

Retrieved on: 
Thursday, February 15, 2024

YORBA LINDA, Calif., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 7th annual event in the Drug Discovery & Development Virtual Event Series. Hosted on February 21st and free to attend, attendees will experience the forefront of pharmaceutical innovation joining industry and academic leaders from around the world debating the latest, insightful scientific breakthroughs in this ever-evolving field.

Key Points: 
  • Focusing from pre-clinical development to clinical development, advances in the field of drug discovery and development will be explored shaping current and future challenges in drug research
    YORBA LINDA, Calif., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Labroots , the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 7th annual event in the Drug Discovery & Development Virtual Event Series .
  • The 2024 informative agenda covers a range of sessions spanning areas including Emerging Modalities in Drug Discovery and Preclinical Development, New Methods in Pharmacogenomics, and Biomarker Applications.
  • Use the hashtag #LRdrug to follow the conversation and connect with other members of the global Drug Discovery & Development community!
  • Follow @DrugDiscoveryLR on Twitter and @DrugDiscoveryandDevelopment on Facebook to connect with our specialist Drug Discovery & Development writers and stay up to date with the latest Trending News in Drug Discovery & Development.

Thermo Fisher Scientific Launches New Ion Chromatography Instrument to Improve Reliability, Efficiency, and Functional Adaptability for Labs

Retrieved on: 
Wednesday, February 14, 2024

To support a wider range of ion chromatography analysis with one instrument, Thermo Fisher Scientific Inc., today launched the Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography (IC) system, helping to make ion analysis simpler and more intuitive for labs of all sizes.

Key Points: 
  • To support a wider range of ion chromatography analysis with one instrument, Thermo Fisher Scientific Inc., today launched the Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography (IC) system, helping to make ion analysis simpler and more intuitive for labs of all sizes.
  • The new analytical instrument is designed to be easily reconfigurable, providing those who require determination of ionic and small polar compounds with a one stop shop for consistent, reliable ion analysis.
  • The Dionex Inuvion system helps meet labs’ needs to operate more efficiently with easily configurable workflows and a small footprint.
  • For more information about the Dionex Inuvion IC system, including technical specifications and applications, please visit www.thermofisher.com/inuvion .

Thermo Fisher Scientific Expands GMP Laboratory Service Offerings with Biosafety Testing Including Mycoplasma Testing

Retrieved on: 
Tuesday, February 13, 2024

This new service, offered by the analytical testing service of the clinical research business, ensures biopharmaceutical products are free of contaminants, helping customers deliver safe medicines for patients.

Key Points: 
  • This new service, offered by the analytical testing service of the clinical research business, ensures biopharmaceutical products are free of contaminants, helping customers deliver safe medicines for patients.
  • “There is a growing need globally for biosafety testing, including for new cell and gene therapy targets being discovered and as treatments expand.
  • To ensure their safety, regulatory requirements mandate testing for the presence of pathogens, including mycoplasma.
  • The PPD Laboratory services team’s GMP lab in Middleton offers fully integrated solutions for pharmaceutical product development, including method development and validation, compendial verifications, stability testing, quality control and release testing.

Molecular Assemblies Announces the Appointment of Two Industry Leaders to Its Commercial-Technology Advisory Board

Retrieved on: 
Tuesday, February 13, 2024

"With the deep knowledge, wisdom, and experience commercializing transformative life science products, the CTAB enables Molecular Assemblies to identify emerging opportunities and trends in the life sciences industry that can be solved with our breakthrough nucleic acid-based products," said Larry Stambaugh, Board Chair of Molecular Assemblies.

Key Points: 
  • "With the deep knowledge, wisdom, and experience commercializing transformative life science products, the CTAB enables Molecular Assemblies to identify emerging opportunities and trends in the life sciences industry that can be solved with our breakthrough nucleic acid-based products," said Larry Stambaugh, Board Chair of Molecular Assemblies.
  • "Molecular Assemblies is helping accelerate the life science industry by removing one of the largest bottlenecks in R&D – the availability of long, pure, accurate oligonucleotides," said Todd C. Peterson, Ph.D., CTAB Chair and MAI Board Director.
  • He is currently Founder and Principal at GenApex Bio, a life sciences Board service and advisory practice.
  • His extensive experience includes leadership roles at Sigma-Aldrich and Genome Systems, where he made significant contributions to the genomics field.

Gurit announces Dr. Javier Perez Freije as the new CFO and Karen Glauser as the new Group Head of HR

Retrieved on: 
Tuesday, February 13, 2024

Gurit (SIX Swiss Exchange: GURN) - The Board of Directors of Gurit Holding AG has appointed Dr. Javier Perez Freije as the new Chief Financial Officer (CFO) and Karen Glauser as the new Group Head of Human Resources.

Key Points: 
  • Gurit (SIX Swiss Exchange: GURN) - The Board of Directors of Gurit Holding AG has appointed Dr. Javier Perez Freije as the new Chief Financial Officer (CFO) and Karen Glauser as the new Group Head of Human Resources.
  • Javier joins Gurit Holding AG from the Mikron Group as of May 1, 2024.
  • Javier will take on the function as CFO of Gurit Holding AG from Philippe Wirth who will leave Gurit end of March 2024.
  • Karen takes on the function as Group Head of HR of Gurit Holding AG from Hannes Haueis who left Gurit end of November 2023.

Next-Generation Sequencing Emerging Clinical Applications and Global Markets, with Profiles of Leading Players Illumina, Thermo Fisher Scientific, QIAGEN, Agilent Technologies and BGI Genomics - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024

The "Next-Generation Sequencing: Emerging Clinical Applications and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Next-Generation Sequencing: Emerging Clinical Applications and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The NGS platform enables companies to expand the menu of disorders/diseases over time after initial launch of a test.
  • The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents, and companies.
  • This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing.

Multiply Labs and Thermo Fisher Scientific Expand Partnership to Automate Cell Expansion and Separation in Cell Therapy Manufacturing

Retrieved on: 
Monday, February 12, 2024

Through integration with Multiply Labs' robotic technology, Thermo Fisher Scientific’s advanced, industry-leading cell therapy instruments, including the Thermo Scientific™ Heracell™ VIOS Automated Access CO2 Incubator and the Gibco™ Cell Therapy Systems (CTS™) Rotea™ Counterflow Centrifugation System can now be fully automated for cell therapy manufacturing.

Key Points: 
  • Through integration with Multiply Labs' robotic technology, Thermo Fisher Scientific’s advanced, industry-leading cell therapy instruments, including the Thermo Scientific™ Heracell™ VIOS Automated Access CO2 Incubator and the Gibco™ Cell Therapy Systems (CTS™) Rotea™ Counterflow Centrifugation System can now be fully automated for cell therapy manufacturing.
  • Furthermore, by automating Thermo Fisher’s CTS Rotea Counterflow Centrifugation System, key manufacturing steps including upstream and downstream cell processing, can be performed automatically.
  • Fred Parietti, PhD, Co-Founder and CEO of Multiply Labs, expressed enthusiasm about the collaboration's potential impact on cell therapy manufacturing.
  • The ongoing partnership with Thermo Fisher plays a crucial role in turning this vision into reality, advancing the realization of cell therapy for the benefit of patients.”

The Foundation for the National Institutes of Health Launches First Public-Private Partnership for Early Detection of Preeclampsia

Retrieved on: 
Monday, February 12, 2024

The Foundation for the National Institutes of Health (FNIH) today announces the launch of a new public-private partnership to develop tools to identify pregnant women at high risk of early-onset preeclampsia.

Key Points: 
  • The Foundation for the National Institutes of Health (FNIH) today announces the launch of a new public-private partnership to develop tools to identify pregnant women at high risk of early-onset preeclampsia.
  • Preeclampsia is a serious pregnancy-related hypertensive disorder that can lead to maternal and neonatal deaths and long-term negative health outcomes.
  • The disorder is becoming more prevalent in the United States, with women of color more likely to be affected and experience poor outcomes.
  • Currently, preeclampsia risk is determined early in pregnancy using a combination of maternal medical history and clinical risk factors.

PHC Holdings Corporation and Senseonics Announce Appointment of Brian Hansen as President of CGM at Ascensia Diabetes Care

Retrieved on: 
Tuesday, February 6, 2024

PHC Holdings Corporation (TSE:6523) (hereafter PHCHD), the parent company of Ascensia Diabetes Care , a global diabetes care company, along with Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that diabetes industry veteran Brian Hansen has been appointed to the newly created role of President of CGM at Ascensia Diabetes Care, effective February 6, 2024.

Key Points: 
  • PHC Holdings Corporation (TSE:6523) (hereafter PHCHD), the parent company of Ascensia Diabetes Care , a global diabetes care company, along with Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that diabetes industry veteran Brian Hansen has been appointed to the newly created role of President of CGM at Ascensia Diabetes Care, effective February 6, 2024.
  • Ascensia is the exclusive global distributor of the Eversense® E3 CGM system developed and manufactured by Senseonics.
  • View the full release here: https://www.businesswire.com/news/home/20240206408169/en/
    Mr. Hansen will be responsible for the global commercialization and growth of the innovative Eversense CGM, currently available in the U.S. and select European markets.
  • The full year 2024 growth outlook will be provided in the second quarter 2024 following an assessment of the current commercial plan by the new President of CGM at Ascensia Diabetes Care.

PHC Holdings Corporation and Senseonics Announce Appointment of Brian Hansen as President of CGM at Ascensia Diabetes Care

Retrieved on: 
Tuesday, February 6, 2024

PHC Holdings Corporation (TSE: 6523) (hereafter PHCHD), the parent company of Ascensia Diabetes Care, a global diabetes care company, along with Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that diabetes industry veteran Brian Hansen has been appointed to the newly created role of President of CGM at Ascensia Diabetes Care, effective February 6, 2024.

Key Points: 
  • PHC Holdings Corporation (TSE: 6523) (hereafter PHCHD), the parent company of Ascensia Diabetes Care, a global diabetes care company, along with Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that diabetes industry veteran Brian Hansen has been appointed to the newly created role of President of CGM at Ascensia Diabetes Care, effective February 6, 2024.
  • Ascensia is the exclusive global distributor of the Eversense® E3 CGM system developed and manufactured by Senseonics.
  • Mr. Hansen will be responsible for the global commercialization and growth of the innovative Eversense CGM, currently available in the U.S. and select European markets.
  • The full year 2024 growth outlook will be provided in the second quarter 2024 following an assessment of the current commercial plan by the new President of CGM at Ascensia Diabetes Care.